Full Text View
Tabular View
No Study Results Posted
Related Studies
Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload
This study has been completed.
Study NCT00235391   Information provided by Novartis
First Received: October 6, 2005   Last Updated: November 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Thalassemia
Sickle Cell Disease
Diamond Blackfan Anemia
Myelofibrosis
Additional conditions recognized in this trial
Anemia
Anemia, Diamond-Blackfan
Anemia, Sickle Cell
Iron Overload
Myeloid Metaplasia
More general conditions related to this trial
Anemia, Aplastic
Anemia, Hemolytic
Anemia, Hemolytic, Congenital
Anemia, Hypoplastic, Congenital
Bone Marrow Diseases
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies
Iron Metabolism Disorders
Lymphatic Diseases
Metabolic Diseases
Myeloproliferative Disorders
Red-Cell Aplasia, Pure
Splenic Diseases
Interventions listed in this trial
Deferasirox
More general drug interventions related to this trial
Chelating Agents
Iron Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services